Neuroscientific Biopharmaceuticals positioned for Alzheimer’s breakthrough
Conditions like dementia and Alzheimer's disease have the most likelihood of a medical breakthrough in the next 10
News
Alzheimer
- About
- News and media
- Upcoming Events
- Recent Events
- Investment Webcasts
- Trading Webcasts
- The Insider
- Meet the CEOs
- Meet the Fund Manager
- Merewether Capital
- OC Funds Management
- Horizon 3 Biotech
- Ellerston Capital
- Thorney Investment Group
- TAMIM Asset Management
- Technical Investing
- Armytage Private Limited
- Eley Griffiths Group
- Pengana Capital Group
- Eiger Capital
- Capital H Management
- NAOS Asset Management
- K2 Asset Management
- Viriathus Australia
- Cyan Investment Management
- Gleneagle Securities
- Yarra Capital Management
- OC Funds Management
- Arnott Capital
- ASX Company Webcasts
- INVESTMENTS
- OPEN INVESTMENTS
- RECENT INVESTMENTS
- Kalinda Wholesale Investment
- Gateway – Series 34
- Dispersion Series 9
- Diversified Commodities Index Series 5
- Mrs Clucks Wholesale Investment
- Wellnex Life Shortfall Placement
- Wattle Health Rights issue
- Registry Direct Shortfall Placement
- Yumble Kids
- TZ Limited Rights Issue
- TZ Limited Placement
- VHM Limited
- BlackRock Multi Asset Strategy
- Connec
- Techgen Initial Public Offering
- Far East Gold
- Red Piranha
- REACH WHOLESALE
- Trading
- Reach Corporate
- CONTACT